Hep C: Public Health Achievement Requires Immediate Application of Interventions

Video

We've had a 150% increase in the number of new cases of hepatitis C in the country, and almost all of those cases are among persons less than 30 years of age," John W. Ward, MD, of CDC said.

John W. Ward, MD, from the CDC said that his team has been working with the Institute of Medicine to "lay out the blueprint" for what's necessary to eliminate hepatitis C in the country. "We have the drugs that can prevent the liver disease, the liver cancer that kills people with hepatitis c, and we have interventions that can interrupt transmission. So, let's put all those together and truly eliminate this from the country," Ward said.

Ward continued to explain that some states, like New York, have already gotten the message about how hepatitis C can be eliminated and are already taking action of their own while they wait for national reporting. They’re bringing together clinicians, health system experts, policy makers, and community organizations to really develop a community-based approach to elimination.

At CROI 2017, Ward shared with MD Magazine, that researchers need to turn their attention toward the rising number of young people becoming infected with hepatitis C. "We have an opioid crises around the world, meaning many young people began using opioids and inject themselves, leading to transmission among people who are sharing that injection equipment. We've had a 150% increase in the number of new cases of hepatitis C in the country, and almost all of those cases are among persons less than 30 years of age," Ward concluded.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.